Regulation of tobacco by the U.S. Food and Drug Administration

Novan Provides Corporate Update and Reports Third Quarter 2021 Financial Results

Retrieved on: 
Wednesday, November 10, 2021
NDA, Molluscum contagiosum, MBA, Doctor of Philosophy, Acne, Food, Severe acute respiratory syndrome coronavirus 2, SB206, COVID-19, Regulation of tobacco by the U.S. Food and Drug Administration, Novin, Company, GLOBE, Toxicity, Webcast, Nasdaq, Marketing, FDA, Sulfur, Management, Pharmaceutical industry

DURHAM, N.C., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today announced its financial and operating results for the quarter ended September 30, 2021 and provided a corporate update. The Company will host a conference call and webcast, today, November 10, 2021, at 8:30 a.m. ET (details below).

Key Points: 
  • ET
    DURHAM, N.C., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Novan, Inc. (the Company or Novan) (Nasdaq: NOVN), today announced its financial and operating results for the quarter ended September 30, 2021 and provided a corporate update.
  • Ended the third quarter of 2021 with a total cash and cash equivalents balance of $60.0 million and positive working capital of $48.8 million.
  • As of September 30, 2021, Novan had a total cash and cash equivalents balance of $60.0 million and positive working capital of $48.8 million.
  • During the second quarter of 2021, the Company recognized a $1.0 million gain on debt extinguishment related to the forgiveness of its Paycheck Protection Program loan in June 2021.

DGAP-News: Epigenomics AG publishes financial results for the first nine months 2021

Retrieved on: 
Wednesday, November 10, 2021
Email, Biobank, Epigenomics AG, Cancer, EPI, CMS, Colorectal cancer, Clinical trial, News, FSE, OTCQX, Technology, CE marking, Food, Liver cancer, Trial of the century, EDT, IFRS, Regulation of tobacco by the U.S. Food and Drug Administration, EBITDA, Sale, Company, Research, 970, ECX, CET, EUR, AG, Webcast, DNA, Marketing, FDA, DGAP, Security (finance), Film, Cryptocurrency, Online shopping, Life insurance

Berlin (Germany) and San Diego, CA (U.S.A.), November 10, 2021 - Epigenomics AG (FSE: ECX, OTCQX: EPGNY, the "Company") today reported financial results (IFRS, unaudited) for the first nine months of 2021.

Key Points: 
  • Berlin (Germany) and San Diego, CA (U.S.A.), November 10, 2021 - Epigenomics AG (FSE: ECX, OTCQX: EPGNY, the "Company") today reported financial results (IFRS, unaudited) for the first nine months of 2021.
  • Cash consumption decreased to EUR 3,598 thousand in the first nine months of 2021 (9M 2020: EUR 7,492 thousand).
  • The financial report for the first nine months of 2021 is available on the Epigenomics' website at: https://www.epigenomics.com/news-investors/financial-reports/ .
  • Epigenomics AG will host a conference call for analysts and investors today at 4.00 pm (CET) / 10.00 am (EDT).

Terns Reports Positive Top-line Results from Phase 1 Proof of Concept Clinical Trial of THR-β agonist TERN-501

Retrieved on: 
Tuesday, November 9, 2021
Liver disease, Safety, PD, Fatty liver disease, LDL, Steatosis, Terminology, Disease, Food, FXR, N.U.D.E.@ Natural Ultimate Digital Experiment, Risk, SAD, AASLD, Cardiotoxicity, COVID-19, Research, Regulation of tobacco by the U.S. Food and Drug Administration, Triglyceride, Annual report, Liver, Chronic liver disease, NASH, Company, Tern, VAP-1, Metabolism, DDI, Fibrosis, THR, Patient, Fast Track, Head, FDA, SHBG, Pharmaceutical industry

FOSTER CITY, Calif., Nov. 09, 2021 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis (NASH) and other chronic liver diseases, today reported positive top-line results from a Phase 1 clinical trial of TERN-501, a thyroid hormone receptor beta (THR-β) agonist in development for the treatment of patients with NASH.

Key Points: 
  • Additional data from the SAD cohorts will be presented at AASLD The Liver Meeting Digital Experience in November 2021.
  • Preliminary PK results support the co-administration of TERN-101 and TERN-501 in NASH patients, with no apparent need for dose adjustment.
  • The TERN-501 proof of concept data are highly encouraging and indicate potent liver target engagement and the potential for broad benefits in NASH patients.
  • Terns pipeline includes three clinical stage development programs including an FXR agonist, a VAP-1 inhibitor and a THR- agonist, and a preclinical GLP-1 receptor agonist program.

Pliant Therapeutics Provides Corporate Update and Reports Third Quarter 2021 Financial Results

Retrieved on: 
Tuesday, November 9, 2021
Compliance, Safety, Fatty liver disease, Biomarker, Private Securities Litigation Reform Act, Therapy, Plasma, News, TGF, Government, PET, Financial condition report, Clinical trial, SAN, Food, Investment, BAL, COVID-19, Muscular dystrophy, Research, Facebook, Regulation of tobacco by the U.S. Food and Drug Administration, Annual report, PSC, YouTube, Risk, IPF, Primary sclerosing cholangitis, Interim, Â, Twitter, Idiopathic pulmonary fibrosis, Partnership, Company, NASH, GLOBE, QLF, LinkedIn, ELF, SEC, Pharmacokinetics, Cirrhosis, Oncology, Fibrosis, Analysis, Result, Nasdaq, Patient, Integrin, ALP, Conversation, Orphan, Pharmaceutical industry, Medical imaging

SOUTH SAN FRANCISCO, Calif., Nov. 09, 2021 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX) (the Company), a clinical stage biotechnology company focused on discovering and developing novel therapeutics for the treatment of fibrosis, today provided a corporate update and reported third quarter 2021 financial results.

Key Points: 
  • SOUTH SAN FRANCISCO, Calif., Nov. 09, 2021 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX) (the Company), a clinical stage biotechnology company focused on discovering and developing novel therapeutics for the treatment of fibrosis, today provided a corporate update and reported third quarter 2021 financial results.
  • Enrollment is currently on track to be completed by the end of 2021 with topline data anticipated by mid-2022.
  • Based on additional safety and pharmacokinetic data from the Phase 1a study, Pliant initiated an extension of the Phase 1b study.
  • Pliant Therapeutics is a clinical stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis.

Aerie Pharmaceuticals to Participate in Upcoming Investor Conferences

Retrieved on: 
Tuesday, November 9, 2021
FDA, Health, Research, Pharmaceutical, Science, Optical, Benjamin, Glaucoma, Aerie Pharmaceuticals, III, Hotel manager, Conjunctivitis, NASDAQ, Food, Diabetic retinopathy, Regulation of tobacco by the U.S. Food and Drug Administration, Medication, Ocular hypertension, Interim, Retina, Netarsudil, Pharming, PGA, Ophthalmology, IOP, Patient, Latanoprost, FDA, Aerie, Pharmaceutical industry

Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and retinal diseases, today announced that the Benjamin McGraw, III, Pharm.D., Interim Executive Chairman, will participate in the following virtual investor conferences.

Key Points: 
  • Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and retinal diseases, today announced that the Benjamin McGraw, III, Pharm.D., Interim Executive Chairman, will participate in the following virtual investor conferences.
  • Select presentations will be available live and for replay viewing by visiting Aeries website at http://investors.aeriepharma.com .
  • Aerie is an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and retinal diseases.
  • In clinical trials of Rhopressa, the most common adverse reactions were conjunctival hyperemia, corneal verticillata, instillation site pain, and conjunctival hemorrhage.

Electromed, Inc. Announces Fiscal 2022 First Quarter Financial Results

Retrieved on: 
Tuesday, November 9, 2021
Biotechnology, Medical Devices, Other Health, Health, Medical Supplies, Private Securities Litigation Reform Act, ERP, SG, Investor relations, R, Security (finance), Eye, Meal, Sumathi Best Television Current Reporting Award, Food, Income, Growth, Exercise, COVID-19, Centers for Medicare & Medicaid Services, International, Forward-looking statement, Regulation of tobacco by the U.S. Food and Drug Administration, Program, Annual report, Travel, Hospital, Company, U.S. Securities and Exchange Commission, Awareness, Research, Center, NYSE, Interest, Marketing, Patient, Intellectual property, Airline, Pharmaceutical industry, Medical device

Electromed, Inc. (Electromed or the Company) (NYSE American: ELMD), a leader in innovative airway clearance technologies, today announced financial results for the three months ended September 30, 2021 (Q1 FY 2022).

Key Points: 
  • Electromed, Inc. (Electromed or the Company) (NYSE American: ELMD), a leader in innovative airway clearance technologies, today announced financial results for the three months ended September 30, 2021 (Q1 FY 2022).
  • Distributor revenue decreased 12.4% to $156,000 in Q1 FY 2022, compared to $178,000 in Q1 FY 2021. International revenue increased 33.3% to $112,000 in Q1 FY 2022, from $84,000 in Q1 FY 2021.
  • Income tax expense totaled $108,000 in Q1 FY 2022, compared to $137,000 in the same period of the prior year.
  • Management will host a conference call on Tuesday, November 9, 2021 at 4:00 pm CT (5:00 pm ET) to discuss Q1 FY 2022 financial results and other matters.

DGAP-News: MorphoSys Announces Departure of Roland Wandeler

Retrieved on: 
Tuesday, November 9, 2021
Constellation, Cancer, Industry, COO, Incyte, Medicine, Clinical trial, U.S. Securities and Exchange Commission, S-1 Executive Committee, FSE, NASDAQ, CEO, Executive Committee, Food, Risk, Lymphoma, Janssen Pharmaceuticals, Supervisory board, Regulation of tobacco by the U.S. Food and Drug Administration, FDA, Psoriasis, Annual report, DLBCL, LLC, ASCT, Judgement, ADCP, Antibody, Degenerative disease, FC, Lenalidomide, ADCC, Communication, Apoptosis, Lymphoid leukemia, Patient, Adult, Pharmaceutical industry, Vaccine, MorphoSys, Monjuvi(R) (tafasitamab), MORPHOSYS, MONJUVI(R) (TAFASITAMAB)

Planegg/Munich, Germany, November 9, 2021 - MorphoSys AG (FSE: MOR; NASDAQ: MOR) announced today that Roland Wandeler, Ph.D., has decided to step down from his position as Chief Operating Officer (COO) and member of the MorphoSys Management Board effective December 31, 2021 to pursue other opportunities.

Key Points: 
  • Planegg/Munich, Germany, November 9, 2021 - MorphoSys AG (FSE: MOR; NASDAQ: MOR) announced today that Roland Wandeler, Ph.D., has decided to step down from his position as Chief Operating Officer (COO) and member of the MorphoSys Management Board effective December 31, 2021 to pursue other opportunities.
  • "MorphoSys is now well positioned to continue its growth journey and bring breakthrough therapies to people living with cancer."
  • "It has been my honor to work with the exceptional team at MorphoSys," said Roland Wandeler.
  • Headquartered near Munich, Germany, the MorphoSys Group, including the fully owned U.S. subsidiaries MorphoSys US Inc. and Constellation Pharmaceuticals, Inc., has more than 750 employees.

NANO-X IMAGING LTD. CLASS ACTION REMINDER: Wolf Haldenstein Adler Freeman & Herz LLP reminds investors that a securities class action lawsuit has been filed in the United States District Court for the Eastern District of New York against Nano-X Imaging Lt

Retrieved on: 
Tuesday, November 9, 2021
Microwindows, News, District court, NASDAQ, Food, Telephone, Regulation of tobacco by the U.S. Food and Drug Administration, ARC, Company, GLOBE, Electric Bond and Share Company v. Securities and Exchange Commission, Court, U.S. Securities and Exchange Commission, FDA, Practice of law

All investors who purchased shares of Nano-X Imaging Ltd. and incurred losses are urged to contact the firm immediately at [email protected] or (800) 575-0735 or (212) 545-4774.

Key Points: 
  • All investors who purchased shares of Nano-X Imaging Ltd. and incurred losses are urged to contact the firm immediately at [email protected] or (800) 575-0735 or (212) 545-4774.
  • You may obtain additional information concerning the action or join the case on our website, www.whafh.com .
  • If you have incurred losses in the shares of Nano-X Imaging Ltd., you may, no later than December 6, 2021, request that the Court appoint you lead plaintiff of the proposed class.
  • This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

BioUtah Announces 2021 BioUtah Life Sciences Awards to be Presented at the Virtual Renalytix BioHive Summit

Retrieved on: 
Tuesday, November 9, 2021
Health, Sanyal, Economic development, University, View, Cache Valley, Partner, Pregnancy, Coprime integers, Filtration, MD, PCR, Leadership, Mammography, GE Healthcare, CEO, Food, CE, Investment, COVID-19, Research, Multimedia, Salt Lake, Regulation of tobacco by the U.S. Food and Drug Administration, Proteomics, Association, Partnership, Woman, Ethanolamine, Biotechnology, Utah State University, Hope, SALT, Innovation, Myriad Genetics, Thermo Fisher Scientific, Patient, CTS, Genetics, Outreach, Pharmaceutical industry, Video game, Management

SALT LAKE CITY, Nov. 9, 2021 /PRNewswire/ --BioUtah today announced its 2021 BioUtah Life Sciences award winners.

Key Points: 
  • SALT LAKE CITY, Nov. 9, 2021 /PRNewswire/ --BioUtah today announced its 2021 BioUtah Life Sciences award winners.
  • Five awards will be presented during a special awards session at the virtual 2021 Renalytix BioHive Summit held on Nov. 12.
  • BioUtah's awards recognize innovators, entrepreneurs and leaders who have made significant contributions to the state's life sciences industry.
  • Awards will be presented on Nov. 12, during a virtual ceremony in which pre-recorded videos of the winners will be unveiled.

University of Medicine and Health Sciences to Host Facebook Live Event, "Ask a Microbiologist"

Retrieved on: 
Tuesday, November 9, 2021
Safety, University, 2017 Facebook live streaming incident, Suicide prevention, Science, Student, News, Psychiatry, MD, UMHS, EST, Food, COVID-19, Town hall, List of Facebook features, Regulation of tobacco by the U.S. Food and Drug Administration, COVID-19 vaccine, Microbiologist, University of Medicine and Health Sciences, Q & A, Vaccine, DRS, Faculty, Review, Assistant, Pharmaceutical industry

The Facebook Live event will address the latest news about the COVID-19 pandemic, provide an in-depth look at the development, review and approval process for vaccines and boosters, and tackle common misconceptions.

Key Points: 
  • The Facebook Live event will address the latest news about the COVID-19 pandemic, provide an in-depth look at the development, review and approval process for vaccines and boosters, and tackle common misconceptions.
  • Siam and Cumby will answer questions from the audience during a live Q & A session.
  • Following their presentation, Dr. Siam and Cumby will respond to questions during a live Q & A session.
  • Graduates of UMHS earn a Doctor of Medicine degree (MD) and qualify to practice medicine throughout the United States and Canada.